Stocktoria

Lite Strategy, Inc. LITS

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2003-12-18

Lite Strategy, Inc. (LITS) earns a Piotroski F-score of 2/9 (weak financial health). It pays a dividend yielding 38.16% (safety: no dividend).

Chart by TradingView
16/100
Stocktoria Quality Score · grade D
2/9
Piotroski F — financial health
Altman Z″ — distress risk
47.2%
Dividend yield 5y avg · no dividend

Quality score trend · recomputed for each fiscal year

Piotroski F /9
2 5 2 2 4 2 3 2 4 2 2016201720182019202020212022202320242025
Altman Z″
-1.56 7.00 -1.49 -6.04 1.28 -2.45 -4.01 -8.00 -18.94 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$0.92 as of 2026-08-01 · -81% 1y
$0.92$4.8652-wk
Market cap USD$31M
Dividend yield 5y avg47.2%
Net margin 5y avg-72.7%
Return on equity 5y avg-71.6%
Beta0.04
Employees4

Smart money · insiders, last 12 months

Insiders net sold -$804,274 on the open market · 4 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 9y · down

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 12%
Return on equitystronger than 19%
Revenue growthstronger than 0%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 2/9 tests passed

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
LITSLite Strategy, Inc.2/9-100%
JNJJOHNSON & JOHNSON4/922.9+6%
LLYELI LILLY & Co7/955.1+44.7%
MRKMerck & Co., Inc.4/917.4+1.3%
PFEPFIZER INC4/917.8-1.6%
ABBVAbbVie Inc.7/9-0.34105.9+8.6%
BMYBRISTOL MYERS SQUIBB CO7/916.7-0.2%

All Manufacturing companies →

About Lite Strategy, Inc.

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

FAQ

Is LITS financially healthy?

Lite Strategy, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).

Does LITS pay a dividend, and is it safe?

Yes. Lite Strategy, Inc. pays a dividend yielding about 38.16% with a None payout ratio, rated “no dividend” for safety.

How profitable is LITS?

In FY2025, Lite Strategy, Inc. had a return on equity of -94.2%.

Is LITS a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on Lite Strategy, Inc.: a Piotroski F-score of 2/9, a dividend yield of 38.16%. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.